Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-09-30
1998-09-22
Weber, Jon P.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435 72, 4352534, 530415, 536 6, A01N 4304, C12P 2104, C12N 120, A23J 100
Patent
active
058114033
ABSTRACT:
The invention relates to a polysaccharide toxin from group B .beta.-hemolytic Streptococcus (GBS) having improved purity. The improved purity of the toxin, 95%, is achieved by the method of purification wherein a bacterial fermentation stock is subjected to chromatography with hydrophobic interaction chromatography (HIC) resin, extraction with a phenol/saline solution followed by ion exchange chromatography. The purified GBS toxin has a molecular weight of about 300 kD and a relative carbohydrate ratio of rhamnose:mannose:galactose:glucose:N-acetyl glucosamine:N-acetyl galactosamine of about 0:1:3:1:1:1, respectively. The GBS toxin is useful for treatment of tumors and other medical conditions.
REFERENCES:
patent: 4242326 (1980-12-01), Sugawara et al.
patent: 4421650 (1983-12-01), Nagasawa et al.
patent: 4771128 (1988-09-01), Ferris et al.
patent: 4882317 (1989-11-01), Marburg et al.
patent: 5010062 (1991-04-01), Hellerqvist
patent: 5059654 (1991-10-01), Hou et al.
patent: 5094960 (1992-03-01), Bonomo
patent: 5225331 (1993-07-01), Jennings et al.
patent: 5302386 (1994-04-01), Kasper et al.
Hellerqvist, C.G. et al., Studies on group B .beta.-hemolytic streptococcus I. Isolation and partial characterization of an extra-cellular toxin., Pediatr. Res., 15:892-898 (1981).
Hellerqvist, C.G. et al., Early Results of a Phase I Trial of CM101 in Cancer Patients., Proceedings of the American Association of Cancer Research Annual Meeting (1995).
Hellerqvist, C.G. et al., Anti-tumor effects of GBS toxin: a polysaccharide exotoxin from group B .beta.-hemolytic streptococcus, J. Canc Res. Clin. Oncol., 120:63-70 (1993).
Michon, F., Multiantennary group-specific polysaccharide of Group B Streptococcus, Biochem., 27:5341-51 (1988).
Paoletti, L.C. et al., Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine, Infect. Immun., 62(8):3236-43 (1994).
Jennings, H. J., et al., Structural Determination and Serology of the Native Polysaccharide Antigen of Type-III Group .beta.-Streptococcus, Canadian J. of Biochem., 58(2):112-120, (1980).
Hanley Susan
Vanderbilt University
Weber Jon P.
LandOfFree
Polysaccharide toxin from Group B .beta.-hemolytic Streptococcus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polysaccharide toxin from Group B .beta.-hemolytic Streptococcus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polysaccharide toxin from Group B .beta.-hemolytic Streptococcus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1621858